News

December 11, 2017

Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology
INDIANAPOLIS, Dec. 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Kimberly Blackwell, M.D., one of the nation's leading breast cancer researchers, will join Lilly Oncology as vice president of early phase development and immuno-oncology on March 12, 2018.  Dr. Blac...

November 13, 2017

Lilly Appoints Philip Johnson to Senior Vice President and Treasurer
INDIANAPOLIS, Nov. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Philip Johnson has been appointed to senior vice president, Finance, and treasurer effective January 1, 2018. Johnson currently serves as vice president for Investor Relations at Lilly. He will report to Joshua Smiley, who will become senior vice president...

October 23, 2017

Lilly announces $72 million investment in diabetes manufacturing in Indianapolis
INDIANAPOLIS, Oct. 23, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to invest $72 million in an insulin manufacturing project at one of its Indianapolis facilities. The investment will be used to replace an existing insulin vial filling line and allow Lilly to meet growing demand for its insulins - including Humalog&...

October 18, 2017

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines
INDIANAPOLIS and TÜBINGEN, Germany, Oct. 18, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac's proprietary RNActive® technology. The companies will us...

October 5, 2017

U.S. Patent and Trademark Office Rules In Lilly's Favor On Alimta Vitamin Regimen Patent
INDIANAPOLIS, Oct. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTO) has ruled in the company's favor regarding patentability of the vitamin regimen for Alimta® (pemetrexed for injection). In the inter partes review (IPR) proceed...

October 5, 2017

Additional Delivery of Insulin Ready for Distribution in Puerto Rico
INDIANAPOLIS, Oct. 5, 2017 /PRNewswire/ -- Today, a new shipment of commercial medicines, including more than 36,000 vials and pens of insulin, arrived in Puerto Rico. The delivery by Eli Lilly and Company (NYSE: LLY) includes 3,000 vials for humanitarian distribution and enough commercial insulin to help re-stock operational pharmacies. Lilly's hu...

September 29, 2017

Lilly Announces Senior Leadership Appointments for Finance, Research & Development and Manufacturing
INDIANAPOLIS, Sept. 29, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a number of leadership changes, promoting several experienced Lilly leaders to executive roles, effective in 2018. Josh Smiley has been promoted to senior vice president and chief financial officer and will become a member of Lilly's executive...

September 7, 2017

Lilly Takes Steps to Streamline Business, Invest in New Medicines and Drive Growth
INDIANAPOLIS, Sept. 7, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced actions to streamline operations to more efficiently focus resources on developing new medicines and to improve its cost structure. Global workforce reductions, including those from a U.S. voluntary early retirement program, are expected to impact approxim...

July 24, 2017

Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy
INDIANAPOLIS and SAN FRANCISCO, July 24, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Nektar Therapeutics (NASDAQ: NKTR) have announced a strategic collaboration to co-develop NKTR-358, a novel immunological therapy discovered by Nektar. NKTR-358, which achieved first human dose in Phase 1 clinical development in March of 2017, has th...

July 12, 2017

Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation
INDIANAPOLIS, July 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has entered into a settlement agreement with generic companies to resolve pending patent litigation in the U.S. District Court for the Eastern District of Virginia regarding the Cialis® (tadalafil) unit dose patent. This patent was previously set to expire on April 2...

July 7, 2017

UK Supreme Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents
INDIANAPOLIS, July 7, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the UK Supreme Court has decided in the litigation relating to alternative salt forms of Alimta® (pemetrexed disodium) that Actavis's products directly infringe Lilly's vitamin regimen patents in the UK, France, Italy and Spain. The UK Supreme Cou...

July 6, 2017

Lilly and Purdue University Announce Strategic Research Collaboration
INDIANAPOLIS and WEST LAFAYETTE, Ind., July 6, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Purdue University today announced a strategic collaboration to conduct life science research. The five-year agreement, where Lilly will provide up to $52 million, marks Purdue's largest strategic collaboration with a single company. "Pur...

June 21, 2017

Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego
INDIANAPOLIS, June 21, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced completion of a $90 million expansion of its Biotechnology Center in San Diego, California. Lilly's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neuro...

Showing 1-13 of 13 Page: 1